Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe COVID-19: The PANCOVID Randomized Clinical Trial.
Rocío MontejanoFernando de la Calle-PrietoMaría VelascoCarlos GuijarroJavier Queiruga-ParadaMaría Jiménez-GonzálezPatricia González-RuanoPatricia MartínezAne Josune GoikoetxeaMarta IbarrolaMarianela CiudadÁngela GutiérrezMiguel TorralbaAna Díaz-BraseroPablo Ryan-MuruaCristina MarceloCristina DíezSofía IbarraEsperanza MerinoVicente EstradaJavier MarcosMaría NovellaMaría A RiveraManuel Ruiz-MuñozMarta de MiguelLlanos SolerMikel Del ÁlamoSantiago MorenoAntonio J CarcasAlberto M BorobiaJose Ramon ArribasPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
Our results do not suggest a beneficial effect of TDF/FTC; nevertheless, they are compatible with the beneficial effect of baricitinib already established by other clinical trials.